Provided by Tiger Trade Technology Pte. Ltd.

Jade Biosciences

21.34
+0.11000.52%
Post-market: 21.340.00000.00%19:30 EDT
Volume:571.85K
Turnover:12.30M
Market Cap:1.36B
PE:-9.11
High:22.12
Open:21.45
Low:21.13
Close:21.23
52wk High:28.00
52wk Low:6.91
Shares:63.60M
Float Shares:47.12M
Volume Ratio:0.62
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3433
EPS(LYR):-3.1931
ROE:-89.18%
ROA:-33.59%
PB:0.47
PE(LYR):-6.68

Loading ...

Jade Biosciences - Public Offering Priced at $15 per Share

THOMSON REUTERS
·
Jun 04

Press Release: Jade Biosciences Announces Pricing of Public Offering of Common Stock

Dow Jones
·
Jun 04

BUZZ-Jade Biosciences falls on planned equity offering

Reuters
·
Jun 04

Jade Biosciences Plans Public Offering

MT Newswires Live
·
Jun 04

Jade Biosciences announces common stock offering, no amount given

TIPRANKS
·
Jun 04

Jade Biosciences plans underwritten public offering of common stock, pre-funded warrants

Reuters
·
Jun 04

Jade Biosciences - Net Proceeds to Fund Clinical Trials, Preclinical Studies, and Corporate Purposes

THOMSON REUTERS
·
Jun 04

Jade Biosciences Announces Proposed Underwritten Public Offering

THOMSON REUTERS
·
Jun 04

Wedbush Keeps Their Buy Rating on Jade Biosciences (JBIO)

TIPRANKS
·
Jun 02

Harrison Lifts JBIO Price Target to $74 on Promising JADE101 Data and Attractive IgA Nephropathy Opportunity

TIPRANKS
·
Jun 02

Jefferies says Jade Biosciences JADE101 data came in line with bull case

TIPRANKS
·
Jun 02

Wedbush Raises Price Target on Jade Biosciences to $45 From $34, Maintains Outperform Rating

MT Newswires Live
·
Jun 01

Jade Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 01

Analysts Are Bullish on Top Healthcare Stocks: Aligos Therapeutics (ALGS), Jade Biosciences (JBIO)

TIPRANKS
·
Jun 01

Jade Biosciences, Inc. : H.c. Wainwright Raises Target Price to $55 From $45

THOMSON REUTERS
·
Jun 01

Jade Biosciences Reports Positive Interim Results in Trial of IgA Nephropathy Drug; Shares Rise

MT Newswires Live
·
Jun 01

BRIEF-Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101

Reuters
·
Jun 01

Jade Biosciences - Phase 3 Registrational Trial Expected to Initiate in First Half of 2027

THOMSON REUTERS
·
Jun 01

Jade Biosciences - Jade101 Well-Tolerated Across All Evaluated Doses

THOMSON REUTERS
·
Jun 01

Jade Biosciences - Jade101 Sustains ~70% Iga Reduction at 12 Weeks After Single Dose

THOMSON REUTERS
·
Jun 01